Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer

Inclusion Criteria: * Female subjects ≥ 21 years of age with histologically confirmed ≥ stage II epithelial ovarian, fallopian tube, and primary peritoneal cancer at diagnosis * Who have not progressed after initial treatment with cytoreductive surgery and at least 4 cycles of platinum-based chemotherapy. OR * Female subjects ≥ 21 years of age with first relapsed epithelial ovarian, fallopian tube, and primary peritoneal cancer (regardless of stage at diagnosis) * Who have not progressed after received at least 4 additional cycles of platinum-based chemotherapy with or without having undergone secondary cytoreductive surgery . Exclusion Criteria: * Subjects with evidence of disease progression according to the GCIG CA125 criteria or RECIST 1.1 criteria. * Subjects who are currently receiving any other concomitant anticancer therapy. * Subjects with evidence of extra-abdominal metastasis.